Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pulmonary arterial hypertension: the burden of disease and impact on quality of life

Marion Delcroix, Luke Howard
European Respiratory Review 2015 24: 621-629; DOI: 10.1183/16000617.0063-2015
Marion Delcroix
1Dept of Respiratory Diseases, KU Leuven, University of Leuven and University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marion.delcroix@uzleuven.be
Luke Howard
2Dept of Cardiac Sciences, Hammersmith Hospital and Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Additional Files
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other disease conditions [12–15]. COPD: chronic obstructive pulmonary disease; SF-36: Medical Outcomes Study 36-item short form.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Scoring system for health-related quality of life (HRQoL) scales [33, 40]. SF-36: Medical Outcomes Study 36-item short form; EQ-5D: EuroQol Group 5-Dimension Self-Report Questionnaire; NHP: Nottingham Health Profile; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; MLHFQ: Minnesota Living with Heart Failure Questionnaire; LPH: Living with Pulmonary Hypertension questionnaire; CHQ: Chronic Heart Failure Questionnaire.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Summary of health-related quality of life scales used in pulmonary arterial hypertension

    ScaleDomainsItems nRecall period
    Generic
     SF-36 [35]8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health36Now to past 4 weeks
     EQ-5D [36]5 domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression5Today
     NHP [37]6 domains: physical mobility, pain, social isolation, emotional reactions, energy level, sleep38At the moment
    Disease-specific
     CAMPHOR [38]3 domains: overall symptoms (energy, breathlessness, mood), functioning, quality of life65Today
     MLHFQ [39]2 domains: physical, emotional214 weeks
     LPH# [40]2 domains: physical, emotional211 week
     CHQ [41]4 domains: dyspnoea, fatigue, emotional function, mastery202 weeks
     emPHasis-10 [42]Unidimensional10At the moment
    • SF-36: Medical Outcomes Study 36-item short form; EQ-5D: EuroQol Group 5-Dimension Self-Report Questionnaire; NHP: Nottingham Health Profile; CAMPHOR: Cambridge Pulmonary Hypertension Outcome Review; MLHFQ: Minnesota Living with Heart Failure Questionnaire; LPH: Living with Pulmonary Hypertension questionnaire; CHQ: Chronic Heart Failure Questionnaire. #: adapted from MLHFQ. Information from [25, 33].

Additional Files

  • Figures
  • Tables
  • Disclosures

    Files in this Data Supplement:

    • L. Howard
PreviousNext
Back to top
View this article with LENS
Vol 24 Issue 138 Table of Contents
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary arterial hypertension: the burden of disease and impact on quality of life
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pulmonary arterial hypertension: the burden of disease and impact on quality of life
Marion Delcroix, Luke Howard
European Respiratory Review Dec 2015, 24 (138) 621-629; DOI: 10.1183/16000617.0063-2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pulmonary arterial hypertension: the burden of disease and impact on quality of life
Marion Delcroix, Luke Howard
European Respiratory Review Dec 2015, 24 (138) 621-629; DOI: 10.1183/16000617.0063-2015
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • The burden of PAH
    • Overview of HRQoL questionnaires
    • PAH management: improving HRQoL
    • Conclusions
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Mucolytics for acute exacerbations of COPD: a meta-analysis
  • Targeting IL-33 and TSLP pathways for novel pulmonary therapeutics
  • Physical activity promotion interventions in chronic airways disease
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society